PT2972368T - Biomarcadores linfocitários para determinação de resposta clínica a terapia celular - Google Patents

Biomarcadores linfocitários para determinação de resposta clínica a terapia celular

Info

Publication number
PT2972368T
PT2972368T PT147126288T PT14712628T PT2972368T PT 2972368 T PT2972368 T PT 2972368T PT 147126288 T PT147126288 T PT 147126288T PT 14712628 T PT14712628 T PT 14712628T PT 2972368 T PT2972368 T PT 2972368T
Authority
PT
Portugal
Prior art keywords
biomarkers
lymphocytic
determining
cell therapy
clinical response
Prior art date
Application number
PT147126288T
Other languages
English (en)
Portuguese (pt)
Inventor
De La Rosa Olga
Lombardo Eleuterio
Dalemans Wilfried
Original Assignee
Tigenix S A U
Tigenix Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A U, Tigenix Nv filed Critical Tigenix S A U
Publication of PT2972368T publication Critical patent/PT2972368T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
PT147126288T 2013-03-15 2014-03-17 Biomarcadores linfocitários para determinação de resposta clínica a terapia celular PT2972368T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382091 2013-03-15

Publications (1)

Publication Number Publication Date
PT2972368T true PT2972368T (pt) 2019-10-18

Family

ID=48044710

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147126288T PT2972368T (pt) 2013-03-15 2014-03-17 Biomarcadores linfocitários para determinação de resposta clínica a terapia celular

Country Status (13)

Country Link
US (2) US10660920B2 (enExample)
EP (2) EP2972368B1 (enExample)
JP (2) JP6567430B2 (enExample)
AU (2) AU2014230014B2 (enExample)
CA (2) CA3188652A1 (enExample)
DK (1) DK2972368T3 (enExample)
ES (1) ES2748825T3 (enExample)
HU (1) HUE046531T2 (enExample)
IL (1) IL241586B (enExample)
PL (1) PL2972368T3 (enExample)
PT (1) PT2972368T (enExample)
SG (1) SG11201507521UA (enExample)
WO (1) WO2014140362A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
ES2748825T3 (es) 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular
JP6811724B2 (ja) * 2015-04-24 2021-01-13 ティジェニクス エス.エー.ユー. 細胞療法に対する臨床応答を決定するためのバイオマーカー
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
TW201831681A (zh) * 2016-11-11 2018-09-01 美商生命科學公司 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
JP7628499B2 (ja) * 2019-02-27 2025-02-10 武田薬品工業株式会社 同種異系療法のための改良された幹細胞集団
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226828B1 (en) * 1999-10-20 2009-12-09 Chugai Seiyaku Kabushiki Kaisha Use of g-csf for inhibiting gvhd
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
EP1871419A4 (en) * 2005-04-22 2009-01-14 Univ Maryland METHOD FOR THE TREATMENT OF TRANSPLANT-AGAINST RECIPIENT DISEASE
WO2012154344A1 (en) * 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
ES2748825T3 (es) 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular

Also Published As

Publication number Publication date
HK1219775A1 (en) 2017-04-13
CA3188652A1 (en) 2014-09-18
JP6883070B2 (ja) 2021-06-09
US11478511B2 (en) 2022-10-25
WO2014140362A3 (en) 2015-04-16
EP2972368A2 (en) 2016-01-20
SG11201507521UA (en) 2015-10-29
US20160067285A1 (en) 2016-03-10
CA2906299A1 (en) 2014-09-18
JP2016516985A (ja) 2016-06-09
HUE046531T2 (hu) 2020-03-30
PL2972368T3 (pl) 2020-03-31
EP3581932A1 (en) 2019-12-18
WO2014140362A2 (en) 2014-09-18
AU2020200807B2 (en) 2021-10-28
AU2014230014A1 (en) 2015-10-29
JP2019215359A (ja) 2019-12-19
AU2020200807A1 (en) 2020-02-20
US10660920B2 (en) 2020-05-26
ES2748825T3 (es) 2020-03-18
AU2014230014B2 (en) 2019-11-14
IL241586B (en) 2019-02-28
DK2972368T3 (da) 2019-10-07
EP2972368B1 (en) 2019-07-24
JP6567430B2 (ja) 2019-08-28
US20200261511A1 (en) 2020-08-20
CA2906299C (en) 2023-04-04

Similar Documents

Publication Publication Date Title
NO2022011I1 (no) Tigolaner/Emodepsid/Praziquantel
IL245573B (en) Cell
DK3049979T3 (da) Struktur-baseret prædiktiv konstruktion
EP2871470A4 (en) ELECTROCHEMICAL BIOSENSOR WITH IMPROVED ACCURACY
DK3011059T3 (da) Biomarkør-identifikation
DK2972351T3 (da) Forbedrede analysemetoder
DK2946246T3 (da) Flerlags elektrokrom indretning med lithium-nikkel-oxid-baseret anode
FR3003076B1 (fr) Supercondensateur electrochimique
EP3009840A4 (en) KIT FOR IMMUNOCHROMATOGRAPHIC DIAGNOSIS
DE112013002360T8 (de) Reagenzinjektor
EP2982408A4 (en) INTERCONNECTS
EP2828282A4 (en) BIOMARKERS
HUE046531T2 (hu) Limfocita biomarkerek sejtterápiára adott klinikai válasz meghatározására
DK2856149T3 (da) Diabetesbiomarkører
EP2980573A4 (en) BIOSENSOR
DK3572090T3 (da) Korttidsvirkende faktor-vii-polypeptider
DK2951552T3 (da) Opfangningsanordning til engangsbrug
IL255243B (en) Biomarkers to determine clinical response to cellular therapy
LT3004891T (lt) Rehospitalizacijos biomarkeris po širdies nepakankamumo
UA26723S (uk) Комплект етикеток для акумулятора
FI20135051L (fi) Energiankulutuksen määrittäminen
FR3014118B1 (fr) Reacteur electrochimique
UA28899S (uk) Акумулятор
UA28816S (uk) Акумулятор
UA28818S (uk) Акумулятор